New drug SYNT-101 tested for safety in first human trial
Knowledge-focused
Recruiting now
This early-phase study tests the safety and tolerability of a new drug called SYNT-101 in healthy adults and those who are overweight or have obesity. About 64 participants will receive either the drug or a placebo. The main goal is to check for side effects and how the drug move…
Phase: PHASE1 • Sponsor: Syntis Bio • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC